Somewhat Positive Press Coverage Somewhat Unlikely to Affect Retrophin (RTRX) Stock Price
Press coverage about Retrophin (NASDAQ:RTRX) has been trending somewhat positive on Wednesday, Accern Sentiment reports. Accern scores the sentiment of news coverage by reviewing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Retrophin earned a daily sentiment score of 0.15 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.3014517747425 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Edited Transcript of RTRX earnings conference call or presentation 1-Mar-17 10:00pm GMT (finance.yahoo.com)
- Retrophin : to Present New Data for Sparsentan at ASN Kidney Week 2017 (4-traders.com)
- Adviser or Accomplice? Spotlight Moves to Shkreli’s Ex-Lawyer (finance.yahoo.com)
- [$$] Jury Selection to Begin in Trial of Martin Shkreli’s Lawyer (finance.yahoo.com)
Retrophin (NASDAQ RTRX) opened at 24.00 on Wednesday. Retrophin has a one year low of $15.55 and a one year high of $25.44. The stock’s 50 day moving average price is $24.06 and its 200-day moving average price is $20.37. The firm’s market cap is $921.24 million.
Retrophin (NASDAQ:RTRX) last announced its quarterly earnings results on Wednesday, August 9th. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.10). The business had revenue of $38.80 million for the quarter, compared to analyst estimates of $37.36 million. Retrophin had a negative return on equity of 7.31% and a negative net margin of 48.74%. Retrophin’s quarterly revenue was up 16.5% compared to the same quarter last year. During the same period last year, the firm earned $0.07 EPS. Analysts forecast that Retrophin will post ($1.13) earnings per share for the current year.
Several equities research analysts recently issued reports on RTRX shares. ValuEngine raised Retrophin from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. BidaskClub raised Retrophin from a “hold” rating to a “buy” rating in a research note on Wednesday, August 16th. Finally, BMO Capital Markets reissued a “buy” rating and issued a $44.00 price objective on shares of Retrophin in a research note on Friday, October 6th. One investment analyst has rated the stock with a hold rating, three have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $36.00.
In other Retrophin news, COO Neil F. Mcfarlane sold 1,378 shares of the business’s stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $22.50, for a total transaction of $31,005.00. Following the transaction, the chief operating officer now owns 13,622 shares of the company’s stock, valued at $306,495. The sale was disclosed in a document filed with the SEC, which is available through this link. 2.41% of the stock is owned by insiders.
Retrophin Company Profile
Retrophin, Inc is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin).
Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.